Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory
syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral …

Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral
drug or vaccine is yet available for the treatment of this disease 1 , 2 – 3 . Several clinical …

Background Ebola virus disease (EVD) is a highly lethal condition for which no specific
treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the …

The characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …

The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …

Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in
clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a …

Background In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with
Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been …

Background Despite repeated outbreaks, in particular the devastating 2014–2016 epidemic,
there is no effective treatment validated for patients with Ebola virus disease (EVD). Among …

Objectives Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19
diagnostics. The high technicalities of nasopharyngeal sampling and molecular assays, as …